Skip to main content

Enzon Pharmaceuticals Value Stock - Dividend - Research Selection

Enzon Pharmaceuticals

ISIN: US2939041081, WKN: 873997

Market price date: 01.06.2021
Market price: 0,57 USD




Enzon Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 09-03-2021
Cash flow
Net operating cash flow -380.000
Capital Expenditures -1
Free cash flow -380.001
Balance sheet
Total Equity 7.360.000
Liabilities & Shareholders equity 48.232.000
Income statement
Net income -1.311.000
Eps (diluted) -0,030
Diluted shares outstanding 51.100.000
Net sales/revenue 52.000

Fundamental ratios calculated on: 01-06-2021

Ratios
Key figures 01-06-2021
Cash flow
P/C -76,65
   
P/FC -76,65
Balance sheet
ROI-2,72
ROE15,26
Income statement
P/E-19,00
Div. Yield0,00%
P/B3,96
P/S560,14


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolENZN
Market Capitalization29.127.000,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2017-09-29,5.0000/3.0000
Internetwww.enzon.com


Description of the company

Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company´s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.enzon.com